Regulatory affairs: Is the Nordic self-care market entering a new era?
Legislative changes in Sweden and Finland are set to reshape how patients access certain medicines. While the reforms are still taking shape, they signal a broader shift towards self-care and could have important implications for pharmaceutical companies operating in the Nordic region.
2.9.2026
By: Juho Bah, Regulatory Affairs Team Lead, Oriola
New patient access models emerge in Sweden and Finland
In Sweden, Parliament has approved legislation introducing the farmaceutsortiment, a new category of non-prescription medicines supplied with mandatory pharmacist counselling. The legislation will enter into force on 1 January 2027.
At the same time, Finland is preparing to expand the availability of selected self-care medicines outside traditional pharmacy channels. The reform is expected to take effect in January 2027, with selected product categories identified as potential candidates for broader retail distribution.
While the approaches differ, both reforms aim to improve access to treatment while maintaining high standards of medication safety.
What could this mean for pharmaceutical companies?
For pharmaceutical companies, the changes may open new possibilities for products that sit between traditional prescription and over-the-counter models. They may also influence how companies approach lifecycle management, patient access strategies and market planning across the Nordic region.
Key questions to consider include:
- Which products could benefit from new access routes?
- Could the reforms create new opportunities for Rx-to-OTC transitions?
- How might labelling, patient information and support materials need to evolve?
- What impact could new distribution models have on commercial strategy
- A strategic discussion for the years ahead
These reforms reflect a continued focus on self-care and access to treatment across the Nordic healthcare landscape. For pharmaceutical companies, the key question is not only how regulations will change, but how those changes may influence portfolio strategy and patient access in the future. Companies that start evaluating the implications early will be better positioned to navigate the transition.
Understanding the opportunities for pharmaceutical portfolios
As the regulatory landscape evolves, pharmaceutical companies will need to assess both the opportunities and practical implications for their portfolios. This includes understanding regulatory requirements, evaluating product suitability and considering how changing access models may affect long-term commercial and market access strategies.
At Oriola Advisory Services, we help pharmaceutical companies navigate regulatory changes across the Nordic markets and assess what they mean in practice for products, patients and business objectives.